Dong-A ST Co., Ltd. (KRX: 170900)
South Korea
· Delayed Price · Currency is KRW
60,100
-300 (-0.50%)
Dec 20, 2024, 3:30 PM KST
Dong-A ST Revenue
Dong-A ST had revenue of 191.50B KRW in the quarter ending September 30, 2024, with 14.95% growth. This brings the company's revenue in the last twelve months to 700.31B, up 9.92% year-over-year. In the year 2023, Dong-A ST had annual revenue of 663.98B with 4.50% growth.
Revenue (ttm)
700.31B
Revenue Growth
+9.92%
P/S Ratio
0.21
Revenue / Employee
415.12M
Employees
1,687
Market Cap
539.91B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 663.98B | 28.59B | 4.50% |
Dec 31, 2022 | 635.39B | 42.16B | 7.11% |
Dec 31, 2021 | 593.23B | 6.50B | 1.11% |
Dec 31, 2020 | 586.73B | -25.58B | -4.18% |
Dec 31, 2019 | 612.31B | 44.88B | 7.91% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionDong-A ST News
- 2 months ago - US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® - Financial Post
- 2 months ago - US FDA Approves Dong-A ST's IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® - Benzinga